Pharmafile Logo
Pharmafocus logo
Advanced Search

Ariad

Showing 12 posts of 12 posts found.

takeda_tokyo_hq

Takeda to acquire Ariad in $5.2 billion deal

January 9, 2017
Manufacturing and Production, Sales and Marketing Ariad, Takeda

Takeda has acquired US drug maker, Ariad Pharmaceuticals, in a deal worth $5.2 billion. Takeda has been looking to bolster …

News
incyte

Incyte acquires Ariad’s European operations in $140 million deal

May 10, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Ariad, Incyte, Operations, buy out, european, iclusig, leukaemia, out-license

Incyte (NASDAQ: INCY) has entered into an agreement with Ariad Pharmaceuticals (NASDAQ: ARIA) that will see the company acquire Ariad’s …

News
manmeetsoni

Ariad names Manmeet Soni CFO

March 14, 2016
Business Services, Sales and Marketing Ariad, CEO, appointment, boardroom, cfo

Ariad Pharmaceuticals Inc (Nasdaq: ARIA) named Manmeet Soni chief financial officer, effective March 21, 2016, succeeding Edward Fitzgerald. Mr Soni will …

Appointment
paris_alternate_high-res_web

Ariad names EMD Serono’s Paris Panayiotopoulos as new president and chief exec

December 21, 2015
Sales and Marketing Ariad, Ariad Pharmaceuticals, EMD Serono, Paris Panayiotopoulos, harvey Berger

The board of directors at Ariad Pharmaceuticals has appointed Paris Panayiotopoulos as president and chief executive from 1 January 2016. …

Appointment
harvey_berger

Ariad founder retires

May 11, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ariad, harvey Berger

Dr Harvey Berger the founder of US pharma firm Ariad Pharmaceuticals has announced his decision to retire as chairman and …

Appointment
Iclusig image

EMA keeps Ariad cancer drug on the market

October 13, 2014
Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib

The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …

News
iclusig image

EMA in new Iclusig probe

December 9, 2013
Sales and Marketing Ariad, EMA, iclusig, leukaemia

Europe’s medicines regulator has begun a new review of Ariad Pharmaceuticals’ leukaemia drug Iclusig, looking in particular at the risk …

News
Iclusig image

Ariad cancer drug pulled amid safety fears

November 1, 2013
Sales and Marketing Ariad, FDA, iclusig, leukaemia

Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …

News
iclusig image

Ariad ditches CML trial

October 21, 2013
Research and Development, Sales and Marketing Ariad, CML, iclusig

Ariad Pharmaceuticals has ditched its late-stage trial of Iclusig in patients with newly-diagnosed chronic myeloid leukemia (CML) after blood clots …

News

Ariad expands in Europe

February 22, 2013
Sales and Marketing Ariad, leukaemia, leukemia

The new European boss of Ariad Pharmaceuticals has sketched out the US firm’s plans for its next-generation leukaemia drug, which …

News

Ariad files new blood cancer drug with the FDA

July 31, 2012
Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer

Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …

News
ariad_slideshow-3

Ariad touts next generation CML treatment

June 29, 2012
Research and Development, Sales and Marketing Ariad, CML, Cancer, Europe, Switzerland

Ariad Pharmaceuticals is to expand into Europe following promising results for an investigational cancer drug. The US biotech firm will …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025